慧擇迴應被列入“預摘牌名單”:積極尋找解決辦法
格隆匯5月5日丨美東時間5月4日,慧擇被美國證券交易委員會(SEC)列入基於《外國公司問責法案》(HFCAA)的暫時性名單,此前,公司於4月27日向SEC正式提交2021年年報。對此,慧擇方面迴應,公司一直在積極尋求可能的解決辦法,以最大程度保護其股東的利益,公司將繼續遵守中國和美國適用的法律法規。根據HFCAA規定,連續三年使用未經美國公眾公司會計監督委員會(PCAOB)審查底稿的審計機構出具年度審計報吿,SEC會禁止公司股票或美國存託憑證在美國證券交易所或場外交易市場進行交易。據悉,中國證監會此前表示,中美雙方已召開多次會議商討解決兩國審計監管合作中的遺留問題,雙方都有意願解決分歧和問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.